Cidara Reports Second Quarter 2016 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
BTIG Expects More Visibility for Cidara Therapeutics' (CDTX) CD101 Soon; Affirms at 'Buy'
August 15, 2016 11:48 AM EDTBTIG affirms Cidara Therapeutics, Inc. (Nasdaq: CDTX) at Buy with a price target of $24 following recent quarterly results and CD101 update.
Analyst Timothy Chiang commented, We expect more visibility on the Co.s novel echinocandin (antifungal) product candidate, CD101, by early 2017 when... More
Needham & Company Reiterates Buy on Cidara Therapeutics (CDTX) Following 2Q Report
August 15, 2016 8:19 AM EDTNeedham & Company reiterated a Buy rating and $20.00 price target on Cidara Therapeutics (NASDAQ: CDTX) following the release of company's 2Q16 financial results and management updates. The Phase 2 non-inferiority STRIVE trial of IV CD101 in Candidemia (NCT02734862) is expected to enroll 90 patients, randomized 1:1:1 to standard... More
